Table 1 Demographics and study participant characteristics, safety set
Characteristics n (%)a | mRNA-1273.222 50 µg N = 511 | mRNA-1273 50 µg N = 376 |
|---|---|---|
Age at screening (years) | ||
Mean (range) | 50.8 (19–89) | 57.6 (20–96) |
Age subgroup | ||
≥18 and <65 years | 406 (79.5) | 226 (60.1) |
≥65 years | 105 (20.5) | 150 (39.9) |
Gender | ||
Male | 195 (38.2) | 186 (49.5) |
Female | 316 (61.8) | 190 (50.5) |
Ethnicity | ||
Hispanic or Latinx | 58 (11.4) | 37 (9.8) |
Not Hispanic or Latinx | 448 (87.7) | 339 (90.2) |
Not reported or unknown | 5 (1.0) | 0 |
Race | ||
White | 426 (83.4) | 322 (85.6) |
Black or African American | 56 (11.0) | 28 (7.4) |
Asian | 11 (2.2) | 16 (4.3) |
American Indian or Alaska Native | 1 (0.2) | 1 (0.3) |
Native Hawaiian or Other Pacific Islander | 0 | 1 (0.3) |
Multiracial | 8 (1.6) | 2 (0.5) |
Other | 6 (1.2) | 2 (0.5) |
Not reported or unknown | 3 (0.6) | 4 (1.1) |
Time between second injection of mRNA-1273 in the primary series and the first booster of mRNA-1273 (days) | ||
n | 509 | 374 |
Median | 251.0 | 242.0 |
IQR | (228–299) | (225–260) |
Time between first booster dose of mRNA-1273 and the second booster (days) | ||
n | 509 | 374 |
Median | 289.0 | 134.0 |
IQR | (258–312) | (118–150) |
Prebooster RT–PCR SARS-CoV-2 | ||
Negative | 488 (95.5) | 366 (97.3) |
Positive | 10 (2.0) | 2 (0.5) |
Missing | 13 (2.5) | 8 (2.1) |
Prebooster antibody to SARS-CoV-2 nucleocapsidb | ||
Negative | 226 (44.2) | 276 (73.4) |
Positive | 282 (55.2) | 100 (26.6) |
Missing | 3 (0.6) | 0 |
Prebooster SARS-CoV-2 statusc | ||
Negative | 216 (42.3) | 267 (71.0) |
Positive | 286 (56.0) | 101 (26.9) |
Positive by both RT–PCR and SARS-CoV-2 nucleocapsidb | 6 (1.2) | 1 (0.3) |
Positive by RT–PCR only | 4 (0.8) | 1 (0.3) |
Positive by SARS-CoV-2 nucleocapsid onlyb | 276 (54.0) | 99 (26.3) |
Missing | 9 (1.8) | 8 (2.1) |
